Malignancy Flashcards
Age at presentation
Leukaemia affects children at all ages
-Early childhood peak
Neuroblastoma and wilms tumour in first 6y
Hodgkin lymphoma and bone tumours in adolescence
Short term side effescts of chemotherapy
Bone marrow suppression Immunosupression Gut mucosal damage Nausea and vomiting Anorexia Alopecia Undernutrition Anaemia Thrombocytopenia and bleeding Neutropenia
Drug specific side effects
Doxorubicin: cardiotoxicity
Cisplatin: renal failure and deafness
Cyclophosphamide: haemorrhagic cystitis
Vincristing: neuropathy
Functions of chemotherapy
Primaru curative .e.g. ALL
Control primary or metastatic disease .e.g. sarcoma, neuroblastoma
Adjuvant treatment for residual disease .e.g. Wilms
High dose therapy with stem cell rescue
Transplantation of bone marrow stem cells to intensify treatment to potentially lethal doses of chemo
Stem cells may be allogeneic or autologous
Principally use in the management of high risk or relapse leukaemia (allogenic) and solid tumours (autologous)
Examples targeted therapies
Tryosine kinase inhibtors .e.g. Imatinib
-Taregtting BCR-ABL fusion gene (philadealphia chromosome ALL and CML)
Monoclonal antibodies .e.g. rituximab
-Anti CD20 for lymphoma
-Anti GD2 for high risk neuroblastoma
Presentation Acute Leukaemia
Peak age 2-5y
Develops over the course of several weeks
Malaise
Anorexia
Anaemia: pallor, lethargy
Neutropenia: infection
Thrombocytopenia: bruising, petechaie, nose bleeds
Bone marrow infiltation: bone pain
reticulo-endothelial: hepatosplenopmegalthy, lymphaneopathy
-superior mediastinal obstruction (uncommon)
CNS: headaches, vominting, nerve palsies
Testis: testicular enlargement
Ix Leukaemia
Abnormal FBC -low Hb -thrombocytopenia Circulating leukaemic blast cells Bone marrow examination for diagnosis Clotting screen (risk of DIC) LP for CSF involvement Chest Xray for mediastinal mass (T cell disease) Blood film
Mx ALL
Blood transfusion for anaemia Allopurinol to protect renal function Stages: -Remission induction: chemo + steroids -Intensification: consolidates remission -CNS: intrathecal chemo -Continuing therapy: ~3y w cotrimaxole prophylaxis -Relapse treatment: high dose chemo +/- irridation
Types of brain tumours
Astrocyoma ~ 40%
Medulloblastoma ~20% midline of posterior fossa
Ependymoma ~8% Posterior fossa
Brainstem glioma ~6% Poor prognosis
Craniophyngioma ~4% Squamous remnant of Ranthke pouch
Atypical teratoid/rhabdoid- rare, aggressive tumour
Poor prognostic factors in ALL
Age: <1y or >10y
Tumour load: >50 x 10^9
Genetics: MLL rearrangement, t4:11 haploidy
Chemo response: persistance of blasts in marrow
MRD: detectable MRD after induction
Presentation brain tumours
Persistent/recurrent vomiting Balance, co-ordination/walking problems Behavioural change Abnormal eye movements Seizures without fevers Abnormal head positioning Persistent or recurrent headache Blurred/double vision Lethargy Deteriorating school performance Delayed or arrested puberty Slow growth Developmental delay/regression Progressive increased in head circumference: separation of suture, bulging fontanelle
Brain tumour site and clinical features
Supratentorial: seziures, hemiplegia, focal neurology
Midline (craniopharyngioma): visual field loss, pituitary dailure (growth, DI, weight gain)
Cerebellar (medulloblastoma, astrocytoma, ependymoma): truncal ataxia, co-ordination difficulty, abnormal eye movements
Brainstem (glioma): cranial nerve defect, pyramidal tract signs, ataxia, no raised ICP
Ix Brain tumour
MRI scan
LP for suspected CSF metastasis (not in raised ICP)
Mx Brain tumour
Surgery first line -treat hydrocephalus -provide tissue diagnosis -maximum resection -Brain and optic pathway no op Radio/chemo variable
Long term effects brain tumours
Neurological disability
Growth and endocrine problems
Neuropsych and educational issues
Types of lymphoma
Hodgkin
Non-hodgkin
Burkitts
Features hodgkin lymphoma
Painless lymphadenopathy -usually in the neck Larger and firm lymph nodes Nodes may cause airway obstruction Long history Systemic features uncommon
Ix Hodgkin lymphoma
Lymph node biopsy
Radiological assessment of nodal sites
Bone marrow biopsy (staging)
Mx Hidgkin lymphoma
Combination chemotherapy
+/- rediotherapy
PET scanning to monitor treatement response
80% cure rate